Table 1 Association between AF-6/afadin immunoreactivity and clinicopathological parameters in 90 uterine endometrial cancers
AF-6/afadin immunoreactivity | |||
|---|---|---|---|
Uterine endometrial cancer | Positive (n = 51) | Negative (n = 39) | Pvalue |
Mean age (range) | 55.9 (32–83) | 58.6 (28–80) | 0.41 |
Histological type | Â | ||
Endometrioid | 51 (100%) | 34 (87.2%) | |
Serous | 0 | 3 (7.7%) | |
Clear | 0 | 2 (5.1%) | 0.21 |
Endometrioid adenocarcinoma | Positive (n = 51) | Negative (n = 34) | P value |
Histological grade | Â | ||
1 | 38 (74.5%) | 11 (32.4%) | |
2 | 11(21.6%) | 13(38.2%) | |
3 | 2 (3.9%) | 10 (29.4%) | P < 0.01 |
Myometrial invasion | Â | ||
No invasion | 14 (27.5%) | 1 (2.9%) | |
Less than half | 26 (51.0%) | 15 (44.1%) | |
More than half | 11 (21.6%) | 18 (52.9%) | P < 0.01 |
Lymph node metastasis | Â | ||
Negative | 48 (94.1%) | 30 (88.2%) | |
Positive | 3 (5.9%) | 4 (11.8%) | 0.57 |
Stage | Â | ||
I | 37 (72.5%) | 25 (73.5%) | |
II | 7 (13.7.8%) | 2 (5.9%) | |
III | 6 (11.8%) | 6 (17.6%) | |
IV | 1 (2.0%) | 1 (2.9%) | 0.82 |